Gilteritinib

Gilteritinib is a pyrazine-2-carboxamide substituted with 3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl, oxan-4-yl, and ethyl groups at positions 3, 5, and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM). Approved by the FDA for treating acute myeloid leukemia in patients with FLT3 gene mutations. It functions as an apoptosis inducer, a receptor protein-tyrosine kinase inhibitor, and an antineoplastic agent. It is classified as an N-methylpiperazine, a piperidine, a secondary amino compound, a monomethoxybenzene, a pyrazine, a primary carboxamide, an aromatic amine, and an oxane.